Pharmaco - Articles

Mohib Rahmani, Managing Principal at operations transformation consultancy Argon & Co highlights the steps that pharmaceutical firms can take to optimise their inventories, unlock substantial stock savings, and free up capital which would otherwise lie dormant on the warehouse floor.
The pandemic spun the pharmaceutical industry into overdrive, with many firms seeing their sales skyrocket as the demand for vaccines and life-saving medicines accelerated. Some of the largest firms in the pharma industry saw their revenues rise to record heights during the pandemic. Now, the challenge is to sustain this growth and ensure that profits are reinvested in research and development to enhance patient outcomes. However, pharma firms have been far from immune to the cash flow challenges gripping globa…

Artificial Intelligence (AI) is transforming industries across the globe, and its impact on the pharmaceutical and biotechnology sectors is particularly profound. By harnessing AI, these industries are not only accelerating drug discovery but also improving the precision and efficiency of therapeutic development.
Artificial Intelligence (AI) is transforming industries across the globe, and its impact on the pharmaceutical and biotechnology sectors is particularly profound. By harnessing AI, these industries are not only accelerating drug discovery but also improving the precision and efficiency of therapeutic development. This article explores the key innovations driven by AI, the technological advancements enhancing gene editing, and the implications for future therapies. Revolutionizing D…

The pharmaceutical industry has long been synonymous with global innovation, driven by the relentless pursuit of new and improved therapies. In recent years, the advent of artificial intelligence (AI) has emerged as a transformative force, offering unprecedented opportunities to streamline drug discovery, optimise clinical trials and enhance patient outcomes.
The pharmaceutical industry has long been synonymous with global innovation, driven by the relentless pursuit of new and improved therapies. In recent years, the advent of artificial intelligence (AI) has emerged as a transformative force, offering unprecedented opportunities to streamline drug discovery, optimise clinical trials and enhance patient outcomes. However, the advent of the EU AI Act can potentially slow down progress to th…

The Internet of Things (IoT) has revolutionised multiple industries, and life sciences is no exception. In pharmaceuticals, biotechnology, clinical research, and medical devices, IoT is driving innovation, improving efficiency, and enabling new approaches to patient care.
The Internet of Things (IoT) has revolutionised multiple industries, and life sciences is no exception. In pharmaceuticals, biotechnology, clinical research, and medical devices, IoT is driving innovation, improving efficiency, and enabling new approaches to patient care. Here, we explore how IoT is being utilised within these critical sectors of the life sciences industry, from smart manufacturing and supply chain management to medical device maintenance… Read the full article on PharmiWeb.Jobs.

The integration of AI into pharmaceutical processes is transforming drug discovery, production, quality control, and supply chain management. The industry is witnessing a paradigm shift, with AI-driven approaches promising to enhance efficiency, reduce costs, and accelerate time-to-market for new drugs.
Artificial Intelligence (AI) is revolutionising various fields within the life sciences, and pharmaceutical manufacturing is no exception. The integration of AI into pharmaceutical processes is transforming drug discovery, production, quality control, and supply chain management. The industry is witnessing a paradigm shift, with AI-driven approaches promising to enhance efficiency, reduce costs, and accelerate time-to-market for new drugs. In this article, we explore the multifaceted impact…

Pharma franchise companies offer a business model where pharmaceutical companies grant individuals or entities the rights to market and sell their products under the company’s brand name. These companies provide a ready-made platform with an established brand, product portfolio, and marketing support, reducing the risk for franchisees. The franchisee benefits from the parent company's research, development, and regulatory approvals, while focusing on sales and distribution in specific regions. This model is cost-effective, as it eliminates the need for manufacturing, and allows quick entry into the pharmaceutical market with lower investment and operational overheads.
The pharmaceutical industry has been experiencing a paradigm shift with the emergence and growth of pharma franchise compani…

After what has been a challenging couple of years for the industry, many of the world’s leading life sciences companies are showing promising signs of recovery, with robust product pipelines and gastronomical investments being committed to researching and developing new and existing treatments.
After what has been a challenging couple of years for the industry, many of the world’s leading life sciences companies are showing promising signs of recovery, with robust product pipelines and gastronomical investments being committed to researching and developing new and existing treatments. In this article, we’ve outlined 10 pharmaceutical companies expected to lead the way when it comes to R&D over the next two years, highlighting their projected R&D spending in 2026. Read the full artic…

If new digital capabilities and top-notch data are critical to process efficiency and competitive advantage, it makes no sense to leave validation (proof that they fulfil what’s required) until the latter stages of the project lifecycle, say Ulrich Lein and Stefani Godoy Herrera of MAIN5.
Any systems relevant to GxP (‘good practices’) must be validated as fulfilling their intended purpose. Yet, too often, computer system validation (CSV) or assurance (CSA) is treated as a distracting compliance exercise, when it could be used to ensure strategic benefits – such as seamless data sharing, and repurposing of data across functional boundaries. The alternative is projects not delivering and having to be reworked, at great expense and delay. Ultimately, it could mean patients failing to gain prom…

Calum Jones (Associate Director – Health Economics) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations
  Calum Jones (Associate Director – Health Economics) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’. On 18th June, I had the distinct pleasure of participating in an expert panel at the HTAi annual meeting held in the picturesque city of Seville, Spain. The session, titled ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economi…

Mtech Access are now part of Petauri. This marks a significant and exciting milestone in our journey, and aligns with our commitment to partnering with industry to bring life-enhancing technologies to market, providing more patient choice and meeting the needs of the healthcare environment.
What this means for our clients: Enhanced services: This strategic move will allow us to offer greater breadth and depth of technical and consulting experience, as well as market coverage for our clients. Continuity and stability: The quality of work and client service that you have come to expect, along with your current projects and relationships, will remain unchanged. Innovative solutions: Leveraging the strengths of the Petauri group, we will build on our commitment to growth and inn…

It would be possible to put a stop to counterfeit medicines. However, simple controls are often still lacking. That's why researchers want to help drug detectives.
It would be possible to put a stop to counterfeit medicines. However, simple controls are often still lacking. That's why researchers want to help drug detectives. In 2015, health officials in the northern region of the Democratic Republic of the Congo stated that they had seen unexplained symptoms in hundreds of children, including convulsions, vertigo, and an erect posture. An emergency team was dispatched by Médecins sans Frontières (Doctors Without Borders) in response to a possible meningitis outbreak. Nevertheless, none of the patients have meningitis infections discovered by the investigators. The children's urine samples…

As AI continues to evolve and integrate into various fields, the life sciences industry has begun leveraging this transformational technology to revolutionise regulatory affairs. Given the complexity and volume of regulatory requirements that companies must comply with, AI offers a promising solution to streamline processes and enhance accuracy.
As AI continues to evolve and integrate into various fields, the life sciences industry has begun leveraging this transformational technology to revolutionise regulatory affairs. Given the complexity and volume of regulatory requirements that companies must comply with, AI offers a promising solution to streamline processes and enhance accuracy. In this article, we delve into how AI is currently used within regulatory affairs in the life sciences, a…

In the intricate landscape of the life sciences, the function of regulatory affairs stands as a linchpin, ensuring not only the seamless introduction of innovative medical solutions to the market but also their compliance with stringent legal and ethical standards. This realm of expertise, pivotal to the pharmaceutical, biotechnology, and broader life sciences industries, serves as the bridge between groundbreaking scientific advancements and their delivery to the global marketplace.
In the intricate landscape of the life sciences, the function of regulatory affairs stands as a linchpin, ensuring not only the seamless introduction of innovative medical solutions to the market but also their compliance with stringent legal and ethical standards. This realm of expertise, pivotal to the pharma…

Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking to infiltrate this key market.
Health economic modelling is fundamental to market access, in both health technology assessment (HTA) and pre and post-launch engagement. It is of value globally, but holds particular importance in markets across Europe, the UK, and Canada, among others. Its application in the US, however, is less established. With a dedicated Health Economics Team, economic modelling is a key area in which Mtech Access support clients. Whilst there are variations in the approaches between HTA markets, we can see commonalities in the requirement for e…

In 2024, the pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry.
In 2024, the pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry. Based on data from Statista, this art…

In the ever-evolving field of pharmaceutical research and development, staying abreast of the latest trends and advancements is paramount. This year, the pharmaceutical industry is marked by groundbreaking innovations, regulatory shifts and unprecedented challenges. From cutting-edge technologies to novel therapeutic approaches, pharmaceutical research, and pharmaceutical approvals in 2024 are redefining how we perceive health care.
In the ever-evolving field of pharmaceutical research and development, staying abreast of the latest trends and advancements is paramount. This year, the pharmaceutical industry is marked by groundbreaking innovations, regulatory shifts and unprecedented challenges. From cutting-edge technologies to novel therapeutic approaches, pharmaceutical research, and phar…

This year, the United States expects to tally more than two million new cancer diagnoses— a first-ever prediction— and more than 611,000 cancer-related deaths. While the death rate from cancer is going down, largely due to improvements in early diagnosis and healthy lifestyle changes, the problem is that fewer people aren’t dying of cancer; that’s because the more people who are diagnosed, statistically the more who will die.
This year, the United States expects to tally more than two million new cancer diagnoses— a first-ever prediction— and more than 611,000 cancer-related deaths. While the death rate from cancer is going down, largely due to improvements in early diagnosis and healthy lifestyle changes, the problem is that fewer people aren’t dying of cancer; that’s because the more peop…

Reviewing the findings of new research into the pharma industry’s evolving aspirations for AI and intelligent automation, ArisGlobal’s Emmanuel Belabe talks to PharmiWeb about how far companies have come with smart transformation of key Safety & Regulatory processes. The international study, of 80+ organisations, spanned every patient treatment process domain, from CROs to young biotechs.
Lucy Walters, PharmiWeb (LW): What stood out most for you in the ArisGlobal 2024 Industry Survey Report[1] findings? Emmanuel Belabe, ArisGlobal (EB): The gap between use and intention. Although 75%+ of surveyed organisations claim they already use some form of ‘advanced automation’ within their processes today - up 13% from 2022 and just 5% in 2020, only 8% have applied next-generation capabilities in “al…

From nurturing a positive work culture to empowering and developing your people for success, Pioneer Group sets out some top tips for building a high-performance team as a life science company.
When it comes to recruitment, the life sciences industry is undoubtedly highly competitive. With demand for skilled professionals often outpacing the supply, attracting (and retaining) qualified candidates with the right expertise can be a significant challenge for many life science companies. From nurturing a positive work culture to empowering and developing your people for success, Pioneer Group sets out some top tips for building a high-performance team as a life science company. Invest in Graduate Programmes Investing in graduate outreach can help to bridge the skills gap in life sciences, and…

Business operations across a range of industries are continuing to feel the impact of the Red Sea shipping crisis. According to research conducted by the British Chambers of Commerce*, 55 per cent of UK exporters and 53 per cent of manufacturers and business-to-consumer (B2C) firms, such as retailers, have faced disruption due to the ongoing conflict.
Business operations across a range of industries are continuing to feel the impact of the Red Sea shipping crisis. According to research conducted by the British Chambers of Commerce*, 55 per cent of UK exporters and 53 per cent of manufacturers and business-to-consumer (B2C) firms, such as retailers, have faced disruption due to the ongoing conflict. The attacks have disrupted global supply chains, forcing shipping companies to divert supplie…